Application Title: Pharmaceutics Core and Investigational Product Development Facility for Translation of TAMU-Discovered Molecules

Lead contact for RDF Application:
Mansoor A. Khan, Ph.D.,
Regents Professor of Pharmaceutical Sciences
Phone- 979-436-0562
Email-mkhan@pharmacy.tamhsc.edu

Key Participating Units: Irma Lerma Rangel College of Pharmacy, College Station Campus
Manufacturing & Mechanical Engineering Tech., Materials Science, College of Engineering

Anticipated Request Amount ($): $1,760,000

Executive summary of this application to utilize Research Development Funds:
Despite enormous strength of outstanding programs at Texas A&M University, our pharmaceutical product development pipeline needs improvement. It requires an integration of chemistry, engineering, life sciences, and clinical sciences for development of small as well as biotech molecules for human, veterinary, and Agri-life products. Too many valuable TAMU discoveries have been hindered or delayed for a practical development from bench to bedside or have gone unnoticed. Patients do not take our discovered drugs as chemicals; they take dosage forms or delivery systems such as tablets, injections, or transdermal patches, among others. At the present time, TAMU has no provisions for formulations development research to promote successful development of our chemical discoveries for clinical studies and FDA filing. However, an important milestone has recently been achieved at TAMU by the recent expansion of the Rangel College of Pharmacy to College Station and development of cGMP facility for pharmaceutical product development. However, we need cGMP compliant equipment (FDA requirement) to be able to covert TAMU discoveries into pharmaceutical products that can be administered to humans in clinical studies. We have the knowledge to comprehensively understand and link the essential components of all dosage forms and delivery systems from various Colleges and components across TAMU. Development of dosage forms requires the most modern understanding of drugs, excipients, processes, products, environment and stability, bioavailability and bioequivalence, and finished dosage form quality with all applicable laws and regulatory considerations. Additionally, pharmaceutical product development requires process scale-up and modernization of all unit operations with process analytical technologies, quality-by-design, and continuous manufacturing through collaborations. Together, with our capabilities in Engineering, Veterinary, and AgriLife Programs, we have the potential to be nationally and internationally recognized for pharmaceutical and biopharmaceutical product development for human and animal use and to serve the State and Federal Governments as advisors on policy development with targeted research. Another critical need is to help establish a pharmaceutics core laboratory to help develop dosage forms and carry out all analytical validations, quality development and monitoring, performance evaluation by in vitro and in vivo methods, and eventual bioavailability and bioequivalence for pre-market research. This will allow TAMU faculty to receive internal support for development of their discoveries with practical INDs, NDAs, BLAs, and ANDAs. It will also dramatically increase the chances of patentability of their inventions and help prepare students for job markets with high competence and entrepreneurial skills. This set-up will present new opportunities from FDA, NIH, NSF, DoD, BARDA/DARPA, industry, and several industrial and state sponsors. Pharmaceutics core laboratories would also be critical for post-market product evaluation. When serious adverse events or fatalities of patients in hospitals in Texas occur, it is critical that we evaluate the product failure modes in addition to other possible metabolic and genomic reasons for the lack of performance. Medications are chemicals that degrade, especially under unfavorable conditions of temperature, humidity, light, uncontrolled manufacturing conditions, or less than desirable excipients and process factors in the development of dosage forms. When such critical events occur, TAMU can identify the root cause of dosage form failures and correct them.